Event: Computational Biotech: From Ideation to Reality | August 23, 2022

Event: Computational Biotech: From Ideation to Reality | August 23, 2022

OpenEye Scientific is holding a biotechnology event to discuss how molecular design software can accelerate your drug discovery project from ideation to reality by growing and advancing your strategy. Early-stage planning can aid with raising venture capital. The event is being held at the Kimpton Marlowe Hotel in Cambridge, Mass. on August 23, 2022. 

 Armillary Front Entrance-1

OpenEye is an industry leader in computational molecular design through rapid, robust, and scalable software, toolkits, technology and design services, and Orion®, the only cloud-native fully integrated software-as-a-service molecular modeling platform.

Speakers

Christopher D. Roberts, PhD, Chief Executive Officer of Civetta Therapeutics

Christopher D. Roberts, PhD, Chief Executive Officer of Civetta Therapeutics. Dr. Roberts brings more than 20 years of leadership experience in the discovery and development of novel therapies in oncology, immunology and other disease areas at Black Diamond Therapeutics, Syros Pharmaceuticals, and GSK. His work has been extensively published.

Dr. Roberts will present, "Innovate to Accelerate: Cutting-Edge Computational Science, Services and Tools to Deliver Drug Discovery Projects."

The presentation reflects on past examples and future aspirations on using computation to make delivering new drug assets better, faster, and cheaper. 

Steve Muchmore, PhD, Head of Drug Discovery Services, OpenEye Scientific

The OpenEye speaker is Steve Muchmore, PhD, Head of Drug Discovery Services. Dr. Muchmore has more than 25 years of pharmaceutical industry experience and a broad background in structural biology and structure-based drug discovery, computational chemistry, and cheminformatics. His presentation provides insight when embarking on a virtual screening campaign to identify potential molecules to acquire, assay, analyze, and advance. The presentation highlights capabilities in both Hit Discovery and Lead Optimization phases of the candidate development process. Dr. Muchmore will cover OpenEye’s Orion Cloud based molecular design platform for early drug discovery efforts that can be accessed directly by your scientists or via our Drug Discovery Services.

The free event will include cocktails and appetizers, the presentations, and a time for discussion afterward.

To register, please click the link below. You must be registered to attend. 

Event Details

Date: Tuesday, August 23, 2022 | 6 - 10 p.m. Eastern Daylight Time (EDT) 

Venue: Kimpton Marlowe Hotel, 25 Edwin H. Land Blvd., Cambridge, Mass.

Speaker/Topic: Chris Roberts, PhD, Chief Executive Officer, Civetta Therapeutics, speaking on "Innovate to Accelerate: Cutting-Edge Computational Science, Services and Tools to Deliver Drug Discovery Projects"

Speaker/Topic: Steve Muchmore, PhD, Head of Drug Discovery Services, OpenEye Scientific, speaking on "Using Virtual Screening to Identify Potential Molecules to Acquire, Assay, Analyze, and Advance"

Register here to attend Computational Biotech: Ideation to Reality: 

https://www.eventbrite.com/e/computational-biotech-ideation-to-reality-tickets-374612214217 

Topic

Related Posts